USS Investment Management Ltd Buys 175,371 Shares of Medtronic PLC $MDT

USS Investment Management Ltd raised its stake in Medtronic PLC (NYSE:MDT) by 7.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,451,244 shares of the medical technology company’s stock after purchasing an additional 175,371 shares during the quarter. Medtronic accounts for about 0.9% of USS Investment Management Ltd’s portfolio, making the stock its 16th biggest position. USS Investment Management Ltd’s holdings in Medtronic were worth $212,376,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Lodestone Wealth Management LLC bought a new stake in Medtronic during the fourth quarter worth $27,000. Anfield Capital Management LLC raised its position in Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after buying an additional 230 shares during the last quarter. Monetary Solutions Ltd bought a new position in Medtronic during the 4th quarter valued at $27,000. Board of the Pension Protection Fund bought a new position in Medtronic during the 4th quarter valued at $29,000. Finally, GoalVest Advisory LLC purchased a new position in Medtronic during the 4th quarter worth $29,000. Institutional investors own 82.06% of the company’s stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Some recent commentary argues Medtronic looks undervalued after its pullback, with bullish write-ups pointing to attractive valuation metrics and the company’s defensive healthcare profile as reasons the stock could offer upside from current levels. Article Title
• Positive Sentiment: Medtronic has also been highlighted by some investors as a long-term holding, helped by the company’s recent FDA 510(k) clearance for its Nellcor pulse oximetry system, which could support its product pipeline and reinforce confidence in future innovation. Article Title
• Positive Sentiment: Several bullish opinion pieces published over the past two days framed MDT as a potentially appealing buy for income and value-oriented investors, which may be helping offset some of the weakness from broader market sentiment. Article Title
• Neutral Sentiment: Other coverage focused on how Medtronic compares with peers like Globus Medical, with analysts suggesting Medtronic may have less upside than faster-growing rivals. That comparison could weigh on sentiment, but it was more of a relative valuation discussion than a direct company-specific setback. Article Title
• Negative Sentiment: Despite the bullish commentary, the stock has been trending lower recently, and a market recap noted MDT’s shares fell while the broader market gained, reinforcing concerns that investors may still be cautious about near-term growth and momentum. Article Title

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MDT. Needham & Company LLC reiterated a “buy” rating and issued a $101.00 target price on shares of Medtronic in a research note on Wednesday, June 17th. Robert W. Baird dropped their price target on shares of Medtronic from $93.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Barclays boosted their price target on shares of Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, April 1st. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Medtronic from $100.00 to $78.00 and set a “hold” rating for the company in a research report on Thursday, June 4th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Seventeen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.00.

Insiders Place Their Bets

In other news, EVP Harry Skip Kiil sold 4,189 shares of Medtronic stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares in the company, valued at $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.26% of the stock is owned by corporate insiders.

Medtronic Stock Down 3.3%

Shares of NYSE MDT opened at $78.25 on Wednesday. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The business’s fifty day moving average price is $79.14 and its 200-day moving average price is $89.37. The stock has a market capitalization of $100.17 billion, a PE ratio of 20.98, a P/E/G ratio of 2.17 and a beta of 0.58.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. During the same quarter in the prior year, the company earned $1.62 EPS. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities research analysts anticipate that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be given a dividend of $0.72 per share. This is a boost from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date is Friday, June 26th. Medtronic’s dividend payout ratio (DPR) is 77.21%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).